Sinocelltech Gains NMPA Clearance for SCTB39-1 Clinical Study in Advanced Solid Tumors
China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received clearance from the National...
Santen’s Ryjunea Gets EU Approval to Slow Myopia Progression in Children
Japan-based Santen Pharmaceutical Co., Ltd. announced that it has received marketing approval from the European...
Takeda’s Shan Guohong Departs to Join BeOne Medicines as Next Career Move
Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical (TYO: 4502) and President of Takeda...
Novo Nordisk Partners with Alibaba Health to Launch Weight Management Hub”
Denmark-based Novo Nordisk (NYSE: NVO) has entered into a partnership with China’s Alibaba Health Information...
Legend Biotech Plans to Disband China Sales Team Amid Carvykti Commercialization Challenges
Reports indicate that China-based Legend Biotech Corporation (NASDAQ: LEGN) plans to disband its China sales...
Pierre Fabre Acquires Global Rights to EGFR Inhibitors PFL-721 and PFL-241 from Antares Therapeutics
France-based Pierre Fabre Laboratories announced the acquisition of global rights to PFL-721 and PFL-241 from...
Hasten Biopharmaceutical Accelerates Asia-Pacific Expansion With 11 MAT Transfers
China-based Hasten Biopharmaceutical Co., Ltd, backed by CBC Group, announced the completion of Market Authorization...
Sino Biopharmaceutical’s TDI01 Receives Breakthrough Therapy Designation for cGVHD Treatment
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Class 1 drug TDI01 has been...
3D Medicines Partners with MGI Tech for Precision Medicine Solutions in Oncology and Infectious Diseases
China-based 3D Medicines (HKG: 1244) announced a strategic collaboration with domestic gene sequencing specialist MGI...
Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia
China’s Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical...
BioMérieux Set to Acquire Day Zero Diagnostics to Boost Infectious Disease R&D Pipeline
France-based BioMérieux is set to acquire the assets of Day Zero Diagnostics, a US-based infectious...
Suzhou GenAssist’s GEN6050X Gains FDA Orphan Drug Status for Duchenne Muscular Dystrophy
China-based Suzhou GenAssist Therapeutic Co., Ltd. announced that its in vivo base editing therapy, GEN6050X,...
BioTroy Therapeutics Secures USD 28M in Series A Funding for CD3L1 Anti-Tumor Drug Development
Shanghai-based BioTroy Therapeutics, a cancer immunotherapy developer, has reportedly secured over RMB 200 million (USD...
GlycoT Therapeutics Partners with Innovent Biologics to Advance ADC Technology
US-based GlycoT Therapeutics LLC last week inked a license agreement with Innovent Biologics, Inc. (HKG:...
Shanghai Escugen and SunRock Biopharma Collaborate on First-in-Class CCR9-Targeted ADC
China-based Shanghai Escugen has partnered with Spain-headquartered SunRock Biopharma, S.L. to co – develop SRB123,...
AbbVie’s Venclexta Fails to Meet Overall Survival Endpoint in HR-MDS Trial
US-based major AbbVie Inc., (NYSE: ABBV) has revealed disappointing data for its Venclexta (venetoclax) in...
Harbour BioMed Wins CNIPA Validation of ‘Binding Molecule’ Patent Amid Dispute
China-based Harbour BioMed (HKG: 2142) announced that the China National Intellectual Property Administration (CNIPA) has...
Roche Advances Prasinezumab to Phase III for Early Parkinson’s Disease
Switzerland-based Roche (SWX: ROG, OTCMKTS: RHHBY) announced its decision to advance prasinezumab, an anti-α-synuclein antibody...
Simcere and NextCure Forge Strategic Alliance to Co-Develop SIM0505 ADC for Solid Tumors
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming and US-headquartered NextCure, Inc. (NASDAQ:...
AstraZeneca’s Oncology Executive Michael Lai to Leave Company in June
Lai Minglong (Michael Lai), head of AstraZeneca’s (AZ, NASDAQ: AZN) global oncology business Dato-DXd and...